Searchable abstracts of presentations at key conferences in endocrinology

ea0090ep870 | Pituitary and Neuroendocrinology | ECE2023

A chordoma of the sphenoidal region: diagnostic challenge

Boubagura Imane , El Mghari Ghizlane , El Ansari Nawal

Introduction and Backgrounds: Pituitary adenomas emerge from the adenohypophysis and are confined to the region of the sella turcica, however, other sites may be involved as a result of extension infiltration, or ectopic location, the ectopic involvement of the sphenoid is rare. Case Report: Our case illustrated a woman patient with an ectopic invasive macroprolactinoma diagnosed as a chordoma of the skull base. In Our case, the first histological examin...

ea0090ep884 | Pituitary and Neuroendocrinology | ECE2023

Hypoplasia of the corpus callosum revealed by staturoponderal growth retardation: about a clinical observation

Boubagura Imane , Rafi Sana , El Mghari Ghizlane , El Ansari Nawal

Introduction: The corpus callosum is the most important of the interhemispheric commissures, its fibers called callosal radiations have a transverse direction. They connect different points of the neocortex. The corpus callosum represents the neopallial commissure; it has indeed a phylogenetic development modeled on that of the neocortex. Hypoplasia of the corpus callosum is included in a rare polymalformative syndrome characterized by agenesis of the corpus callosum (CC), dis...

ea0090ep902 | Pituitary and Neuroendocrinology | ECE2023

Hyperparathyroidism and Prolactinoma: MEN1 or incidental association?

Maryame Benlafqih , Rafi Sana , El Mghari Ghizlane , El Ansari Nawal

Introduction: Primary hyperparathyroidism and prolactinoma can be associated as part of a MEN1. However, the association of the two pathologies can also be seen outside of a syndrome predisposing to endocrine tumors. Case presentation: F.L., a 33-year-old woman followed for end-stage renal failure, during her follow-up hyperparathyroidism was discovered without any idea of the culprit and the victim: is the renal failure secondary to hyperparathyroidism ...

ea0090ep937 | Reproductive and Developmental Endocrinology | ECE2023

Preventing female virilisation: role of antenatal dexamethasone

Bammou Sanaa , Rafi Sana , El Mghari Ghizlane , El Ansari Nawal

Introduction: Antenatal treatment with dexamethasone in pregnancies affected by congenital adrenal hyperplasias (CAH) therefore suppresses fetal androgen production and prevents virilisation of female infants. Antenatal DXM is reported to be efficacious, preventing or ameliorating virilisation in 80–85% of cases.Case report: 23-year-old patient pregnant at 6 weeks, not known of having congenital adrenal hyperplasia (CAH), concept of consanguineous m...

ea0090ep946 | Reproductive and Developmental Endocrinology | ECE2023

46 xy disorders of sex development (dsd): a case report

Elgharroudi Farah , El Ansari Nawal , El Mghari Ghizlane

Introduction: Sexual differentiation depends on a succession of events, each stage of which may be the site of abnormalities resulting in sexual ambiguitý. Case report: 17-year-old female patient, consults for primary amenorrhea. On physical examination the morphotype is female, height is normal, secondary sexual characteristics are Tanner stage 1 with sexual ambiguitý Prader stage 4, No palpable testes with a subpenile Orifice. Pelvic ultrasou...

ea0090ep960 | Thyroid | ECE2023

Rare case of Graves’ disease resistant to methimazole: a case report

Ismail Zahra , Rafi Sana , El Mghari Ghizlane , El Ansari Nawal

Introduction: The treatment of Graves’ disease is represented principally by anti-thyroid drugs, radioiodine ablation or thyroidectomy. Methimazole is the most used drug for the initial treatment. It is rare to encounter patients with resistant hyperthyroidism despite high doses of MMI.Case presentation: A 41-year-old woman was referred to our unit for resistant thyrotoxicosis. She had a confirmed Graves’ disease with positive serum Trab. Whils...

ea0090ep1046 | Thyroid | ECE2023

A fatal case of myxedema coma

Boubagura Imane , Rafi Sana , El Mghari Ghizlane , El Ansari Nawal

Introduction and Backgrounds: Myxedema coma is a severe life threatening form of decompensated hypothyroidism which is associated with a high mortality rate. Infections and discontinuation of thyroid supplements are the major precipitating factors. It’s characterized by a decreased mental status, hypothermia, bradycardia, hypotension, and hypoventilation. Very few cases of Myxedema coma have been reported till date, actual prevalence is unclear with the estimated incidenc...

ea0063p146 | Diabetes, Obesity and Metabolism 1 | ECE2019

Metabolic profile and diabetes in prison

Askaoui Sara , Oukit Loubna , Lmghari Guizlane , El Ansari Nawal

Introduction: The prison environment is a space that involves certain restrictions on prisoners. The diabetic subject requires, however, special attention. The aim of this work is to evaluate the impact of this medium on the glycemic balance and the metabolic profile.Patients and method: Descriptive cross-sectional study carried out on a health campaign day in a penitentiary center, in the men’s sector, and concerned patients with known diabetes fro...

ea0063p232 | Pituitary and Neuroendocrinology 1 | ECE2019

Mammosomatotropic adenoma and acromegaly: about 3 cases

Askaoui Sara , El Mghari Guizlane , Raiss Hanane , El Ansari Nawal

Introduction: Somatotropic adenomas are clinically expressed either by acromegaly or by gigantism according to age of onset. Several histological types are involved. Immunohistochemistry provides conclusive evidence that significant diversity exists between growth hormone secreting (GH) tumors in excess. We report three observations of a particular histological type: mammosomatotropic adenoma.Observation 1: Mrs. M.H., aged 56, hypertensive for 10 years, ...

ea0063p233 | Pituitary and Neuroendocrinology 1 | ECE2019

Silent somatotropic adenoma: about a case

Askaoui Sara , Lmghari Guizlane , Rafi Sana , El Ansari Nawal

Introduction: Somatotropic adenomas are classically a source of hypersecretion of GH and consequently of IGF1 responsible for the clinical signs of acromegaly. Rarely, these adenomas remain ‘silent’, without any obvious clinical manifestation. They can then be detected on the basis of a routine determination of growth hormone under oral glucose tolerance test (GH/OGTT) and insulin growth factor 1 (IGF1) or be diagnosed only to immunohistochemical study as is the case...